{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T10:55:10Z","timestamp":1787223310306,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.lungcan.2022.08.001","type":"journal-article","created":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T19:11:27Z","timestamp":1659813087000},"page":"65-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany"],"prefix":"10.1016","volume":"172","author":[{"given":"Frank","family":"Griesinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"P\u00e9rol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Durand-Zaleski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zacharias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Bosquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"J\u00e4nicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Quantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Groth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Fleitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Calleja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Lacoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda J.","family":"Daumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Penrod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Waldenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doroth\u00e9e","family":"Reynaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Chouaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lungcan.2022.08.001_b0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lungcan.2022.08.001_b0010","unstructured":"GLOBOCAN. Global Cancer Observatory. 2020. Available at: https:\/\/gco.iarc.fr\/. Accessed 13 April 2022."},{"key":"10.1016\/j.lungcan.2022.08.001_b0015","unstructured":"Cancer.Net. Lung cancer \u2013 non-small cell: statistics. 2021. Available at: https:\/\/www.cancer.net\/cancer-types\/lung-cancer-non-small-cell\/statistics#:\u223c:text=NSCLC%20is%20the%20most%20common,be%20diagnosed%20with%20lung%20cancer. Accessed 13 April 2022."},{"issue":"3","key":"10.1016\/j.lungcan.2022.08.001_b0020","doi-asserted-by":"crossref","first-page":"254","DOI":"10.6004\/jnccn.2021.0013","article-title":"NCCN guidelines insights: non-small cell lung cancer, Version 2.2021","volume":"19","author":"Ettinger","year":"2021","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.lungcan.2022.08.001_b0025","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2022.08.001_b0030","unstructured":"ESMO Guidelines for Metastatic NSCLC. European Society for Medical Oncology. (Internet). 2020. Available at: https:\/\/www.esmo.org\/guidelines\/lung-and-chest-tumours\/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer. Accessed 13 April 2022."},{"key":"10.1016\/j.lungcan.2022.08.001_b0035","unstructured":"Auvergne-Rh\u00f4ne-Alpes Guidelines in Thoracic Oncology. ARISTOT 2021 [French]. Available at: http:\/\/referentiels-aristot.com. Accessed 13 April 2022."},{"key":"10.1016\/j.lungcan.2022.08.001_b0040","unstructured":"F. Griesinger, G. Absenger, W. Eberhardt, M. Fr\u00fch, O. Gautschi, W. Hilbe, H. Hoffmann, R.M. Huber, S. Loges, C. P\u00f6ttgen, R. Pritzkuleit, M. Reck, N. Reinmuth, M. Sebastian, C. Waller, J. Wolf, M. Wolf, B. W\u00f6rmann, Lung cancer, non-small cell (NSCLC). Onkopedia 2021. Available at: https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/lungenkarzinom-nicht-kleinzellig-nsclc\/@@guideline\/html\/index.html#ID0EG. Accessed 13 April 2022."},{"issue":"3","key":"10.1016\/j.lungcan.2022.08.001_b0045","doi-asserted-by":"crossref","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","article-title":"Non-small cell lung cancer: current treatment and future advances","volume":"5","author":"Zappa","year":"2016","journal-title":"Transl. Lung Cancer Res."},{"issue":"11","key":"10.1016\/j.lungcan.2022.08.001_b0050","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1002\/ijc.29915","article-title":"Targeted therapies for treatment of non-small cell lung cancer-Recent advances and future perspectives","volume":"138","author":"Minguet","year":"2016","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2022.08.001_b0055","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.lungcan.2022.08.001_b0060","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.lungcan.2022.08.001_b0065","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"10066","key":"10.1016\/j.lungcan.2022.08.001_b0070","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.lungcan.2022.08.001_b0075","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced non-squamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2022.08.001_b0080","unstructured":"European Medicines Agency. Nivolumab BMS European public assessment report. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/opdivo. Accessed 13 April 2022."},{"key":"10.1016\/j.lungcan.2022.08.001_b0085","unstructured":"European Medicines Agency. Keytruda European Public Assessment Report Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/keytruda. Accessed 13 April 2022."},{"key":"10.1016\/j.lungcan.2022.08.001_b0090","unstructured":"European Medicines Agency. Tencentriq European public assessment report. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tecentriq. Accessed 13 April 2022."},{"issue":"14","key":"10.1016\/j.lungcan.2022.08.001_b0095","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.2217\/fon-2019-0025","article-title":"I-O Optimise: a novel multinational real-world research platform in thoracic malignancies","volume":"15","author":"Ekman","year":"2019","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2022.08.001_b0100","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12890-020-01270-z","article-title":"Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative","volume":"20","author":"Soares","year":"2020","journal-title":"BMC Pulm. Med."},{"issue":"5","key":"10.1016\/j.lungcan.2022.08.001_b0105","first-page":"100165","article-title":"Epidemiology and survival outcomes for patients with NSCLC in Scandinavia in the preimmunotherapy era: a SCAN-LEAF retrospective analysis from the I-O Optimise initiative","volume":"2","author":"Ekman","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"issue":"5","key":"10.1016\/j.lungcan.2022.08.001_b0110","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-043442","article-title":"Trends in the prescription of systemic anticancer therapy and mortality among patients with advanced non-small cell lung cancer: a real-world retrospective observational cohort study from the IO optimise initiative","volume":"11","author":"Snee","year":"2021","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.lungcan.2022.08.001_b0115","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s12885-020-06738-z","article-title":"Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis","volume":"20","author":"Hardtstock","year":"2020","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2022.08.001_b0120","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1186\/s12885-018-4958-5","article-title":"Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study","volume":"18","author":"Scherpereel","year":"2018","journal-title":"BMC Cancer."},{"issue":"3","key":"10.1016\/j.lungcan.2022.08.001_b0125","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4103\/atm.ATM_276_16","article-title":"Distribution patterns of the metastases of the lung carcinoma in relation to histological type of the primary tumor: An autopsy study","volume":"12","author":"Milovanovic","year":"2017","journal-title":"Ann. Thorac. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2022.08.001_b0130","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/COC.0000000000000230","article-title":"Brain metastases at presentation in patients with non-small cell lung cancer","volume":"41","author":"Waqar","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2022.08.001_b0135","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/s12885-021-08096-w","article-title":"Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom","volume":"21","author":"Lester","year":"2021","journal-title":"BMC Cancer."},{"issue":"22","key":"10.1016\/j.lungcan.2022.08.001_b0140","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.lungcan.2022.08.001_b0145","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non\u2013small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2022.08.001_b0150","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non\u2013small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2022.08.001_b0155","doi-asserted-by":"crossref","unstructured":"A.G. Robinson, D. Vicente Baz, A. Tafreshi, H. Soto Parra, J. Mazieres, I. Cicin, B. Medgyasszay, J. Rodr\u00edguez-Cid, I. Okamoto, S.S. Lee, R. Ramlau, V. Vladimirov, Y. Cheng, B. Halmos, C. Liu, P. Schwarzenberger, B. Piperdi, L. Paz-Ares, First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407. Presented at the European Lung Cancer Virtual Congress 2021 (25\u201327 March).","DOI":"10.1016\/S1556-0864(21)01939-0"},{"issue":"10","key":"10.1016\/j.lungcan.2022.08.001_b0160","doi-asserted-by":"crossref","first-page":"S1002","DOI":"10.1016\/j.jtho.2021.08.315","article-title":"P10.10 Trends in Treatment Patterns and Survival in Advanced NSCLC Patients Treated at Frankfurt University Hospital in 2012\u20132018","volume":"16","author":"Wolf","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2022.08.001_b0165","unstructured":"US Food & Drug Administration. FDA approves nivolumab plus ipilimumab and chemotherapy for first-line treatment of metastatic NSCLC 2020. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-plus-ipilimumab-and-chemotherapy-first-line-treatment-metastatic-nsclc. Accessed 13 April 2022."},{"key":"10.1016\/j.lungcan.2022.08.001_b0170","unstructured":"Businesswire. Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer. Available at: https:\/\/www.businesswire.com\/news\/home\/20201106005029\/en\/. Accessed 13 April 2022."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222005773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222005773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:02:25Z","timestamp":1759237345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500222005773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":34,"alternative-id":["S0169500222005773"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.08.001","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}